Study identifier:D6997C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (plus 250mg Loading regimen) and 500mg in Postmenopausal Women with ER +ve Advanced Breast Cancer Progressing or Relapsing after Previous Endocrine Therapy
Advanced breast cancer
Phase 2
No
Fulvestrant
Female
143
Interventional
N/A
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Feb 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
Location
Location
Nagoya, Aichi, Japan
Location
Asahi, Chiba, Japan
Location
Chiba, Chiba, Japan
Location
Matsuyama, Ehime, Japan
Location
Fukuoka, Fukuoka, Japan
Location
Kitakyushu, Fukuoka, Japan
Location
Kurume, Fukuoka, Japan
Location
Daito, Fukushima, Japan
Arms | Assigned Interventions |
---|---|
Experimental: 1 Fulvestrant 250 mg intramuscular injection | Drug: Fulvestrant 250 intramuscular injection Other Name: Faslodex Other Name: ZD9238 |
Experimental: 2 Fulvestrant 250mg (Plus 250mg Loading Regimen) | Drug: Fulvestrant 250 intramuscular injection Other Name: Faslodex Other Name: ZD9238 |
Experimental: 3 Fulvestrant 500 mg | Drug: Fulvestrant 500 mg intramuscular injection |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.